Experience
Academisch Ziekenhuis Leiden
University of Western Australia
Represented Sarepta and University of Western Australia in Federal Circuit appeals from interferences related to Exondys 51® (eteplirsen) for Duchenne muscular dystrophy.
Academisch Ziekenhuis Leiden v. University of Western Australia, 16-2262, 17-1078, Fed. Cir.
Academisch Ziekenhuis Leiden v. University of Western Australia
University of Western Australia
University of Western Australia v. Academisch Ziekenhuis Leiden
Sarepta Therapeutics
Nestle USA, Inc.
Pozen Inc. v. Dr. Reddy’s Laboratories Inc.
Horizon Medicines LLC
Dialware Communications, LLC v. Hasbro, Inc.
Dialware Communications, LLC
Cox Communications v. Sprint Communication Co.
Sprint Communication Co.
Hillcrest Laboratories, Inc. v. Movea, Inc.
Hillcrest Laboratories, Inc.
Trading Technologies, Inc. v. CQG, Inc.
Trading Technologies, Inc.
Freedom Wireless v. Boston Communications Group, Inc.
Boston Communications Group, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.